Musculoskeletal/Rheumatology

More patients with uncontrolled gout treated concomitantly with methotrexate and pegloticase maintained therapeutic response at 6 months compared with those receiving pegloticase alone, according to a study published in The Journal of Rheumatology.

In this multicenter, open-label, efficacy and safety study, 14 patients with uncontrolled gout were administered oral methotrexate (15 mg/week) and folic acid (1 mg/day) 4 weeks prior to and throughout treatment with pegloticase.

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

  1. Sep 16, 2020

New gout guidelines may leave gaps in disease management

Although the 2020 American College of Rheumatology guidelines for gout management released in May 2020 are an improvement over the 2012 guidelines, gaps in disease management remain, according to a presentation at the 2020 Congress of Clinical Rheumatology-East.

Journal Scan

  1. Sep 23, 2020

Methotrexate plus pegloticase shows potential for uncontrolled gout

More patients with uncontrolled gout treated concomitantly with methotrexate and pegloticase maintained therapeutic response at 6 months compared with those receiving pegloticase alone, according to a study published in The Journal of Rheumatology.